< Brochure Homepage | Faculty Index | Pathology Homepage

Email ishih@jhmi.edu
Phone (410) 502-7774

Related Websites
Lab Research Website

Richard TeLinde Distinguished Professorship of Gynecologic Pathology

GYN/OB Research Website

Ovarian Cancer Prevention

Ie-Ming Shih, M.D., Ph.D.

Primary Appointment in Pathology;
Secondary Appointment in Pathology;
Member, Gradutate Program in Pathobiology

Dr. Ie-Ming Shih is the Richard TeLinde Distinguished Professor of Gynecologic Pathology at the Johns Hopkins University School of Medicine. Dr. Shih directs the Molecular Genetics Laboratory of Female Reproductive Cancer in the Department of Pathology and co-directs the Breast and Ovarian Cancer Program at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Medical Institutions. Dr. Shih received his M.D. from Taipei Medical University and earned his Ph.D. in pathology from the University of Pennsylvania. Dr. Shih went on to do a clinical fellowship in gynecologic pathology and a research fellowship in cancer genetics at Johns Hopkins before joining the faculty in 2001.

Dr. Shih’s research focuses on molecular and translational studies on various gynecological neoplasms, especially ovarian cancer. His research team helps to elucidate the genomic landscape in ovarian clear cell carcinoma, ovarian low-grade serous carcinoma and uterine serous carcinoma. Dr. Shih has published extensive basic and translational research on gynecologic pathology and oncology, with more than 300 original publications and book chapters. Dr. Shih’s research team has contributed to the discovery and functional characterization of cancer-associated genes and the pathways they control, including ARID1A and Syk in ovarian cancer. Based on molecular genetic analysis in ovarian cancer, his team is exploring new molecular targets and pathways for experimental therapeutics and is initiating new clinical trials based on new findings.

Dr. Shih sits on several advisory boards, such as the NCI Ovarian Task Force of Gynecologic Cancer Steering Committee (for clinical trials on gynecologic cancer), the Ovarian Cancer Research Foundation, and the International Society of Gynecologic Pathology/World Health Organization (WHO) Nomenclature Committee for Gynecologic Neoplasms. In addition to his clinical, research and teaching obligations, Dr. Shih is a passionate photographer (www.shih-photography.com).


Yu Y, Gaillard S, Jude MP, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell, 28:82-96, 2015. PMID: 26096845

Guan B, Suryo Rahmanto Y, Wu RC, Wang Y, Wang Z, Wang TL, Shih IeM. Roles of deletion of arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst. 2014;106(7). PMID: 24899687

Gao M, Uw RC, Herlinger AL, Yap K, Kim JW, Wang TL, Shih IM. Identification of NAC1-regulated genes in ovarian cancer. Am J Pathol, 184:133-140, 2014. PMID:24200849

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IM. Mutational analysis of BRAF and KRAS in ovarian atypical proliferative serous (borderline) tumors and associated peritoneal implants. J Pathol, 232:16-22, 2014. PMID:24307542

Zeppernick F. Ardigheri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IM. BRAF mutation is associated with a specific cell-type with features suggestive of senescence in ovarian serous borderline tumors. Am J Surg Pathol, 38:1603-1611, 2014. PMID: 25188864


Copyright © 2017 Johns Hopkins University. All Rights Reserved